MorphoSys - Nilai bisnis marang pendapatan MOR

The historical EV/Sales trend demonstrates the market valuation of MorphoSys AG, where the latest parameter stands at . This price action is supported by a streamlined supply of antibody components, which minimizes disruptions during testing. Licensing royalties from Monjuvi sales and patent protection form the financial foundation. Simultaneously, the company is developing innovative methods to block tumor growth.
MOR (MorphoSys Corporation): rincian analitis lan laporan miturut indikator

This indicator compares Enterprise Value (EV) to annual revenue, allowing for an assessment of revenue generation efficiency while accounting for debt load and available liquidity. By analyzing the EV/Sales chart, an investor can see how the market values the innovative developments of MorphoSys AG (MOR) in the field of targeted blood cancer therapy relative to current cash flows from antibody sales.